A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer - PubMed
5 hours ago
- #Phase 1 trial
- #Breast cancer
- #Combination therapy
- A phase 1 study evaluated ASTX727 (DNMTi) plus talazoparib (PARPi) in 34 patients with TNBC or HRBC metastatic breast cancer and intact BRCA.
- Myelosuppression was common, with grade ≥3 neutropenia in 42% and dose-limiting toxicity limited to neutropenia; no other significant adverse events were reported.
- No objective responses were observed, but stable disease lasting >4 months occurred in three patients; methylation changes in PBMCs were modest and not dose-dependent.